Amgen recently shared positive results for its Fourier Trial, which is evaluating whether Repatha reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD).
The study met its primary composite endpoint for cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization. The study also met its key secondary composite endpoint for cardiovascular death, non-fatal MI or non-fatal stroke.
"In the GLAGOV study, we demonstrated that Repatha has an effect on atherosclerosis, the underlying cause of cardiovascular disease," Dr. Sean Harper, Amgen's executive vice president of research and development, said. "These FOURIER results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy. Cardiovascular disease remains the number one health burden in the world, and we look forward to sharing these outcomes data with the scientific community at the ACC 66th Annual Scientific Session."
According to an Amgen news release, cardiovascular disease is the world’s leading cause of death. The company notes that around 11 million people with ASCVD or familial hypercholesterolemia in the U.S. alone have uncontrolled levels of low-density lipoprotein (LDL-C) over 70 mg/dL.
Alerts Sign-up